Table 5.
The network meta-analysis of PFS in HRD-positive patients.
| Niraparib | 0.84(0.50, 1.43) | 2.63(1.68, 4.12) |
| 1.19(0.70, 2.02) | Rucaparib | 3.13(2.36, 4.14) |
| 0.38(0.24, 0.60) | 0.32(0.24, 0.42) | Placebo |
The data in bold are statistically significant.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.